Clinical Case Studies in Venous Thromboembolism: Using Direct Oral Anticoagulants for Treatment and Secondary Prevention
Release Date: May 19, 2017
Expiration Date: May 31, 2018
Activity Type: Application-based
CE Credits: 1.0 (0.1 CEU), no partial credit for pharmacists
Activity Fee: Free of charge
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Accreditation for Physicians
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This continuing education activity was planned to meet the needs of clinicians with an interest in venous thromboembolism (VTE), especially primary care providers, emergency room physicians, hospitalists, cardiologists, pulmonologists, vascular surgeons, hematologists, and pharmacists in hospitals and ambulatory care clinics who care for patients with VTE.
Activity Content
Clinical case studies will be used to illustrate the decision-making process regarding the acute treatment and secondary prevention of venous thromboembolism based on recently updated guidelines and clinical trial data. Strategies for overcoming barriers to the appropriate use of direct oral anticoagulants and for ensuring long-term follow-up also will be discussed.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to- Incorporate direct oral anticoagulants (DOACs) into existing venous thromboembolism (VTE) pathways, including strategies for ensuring appropriate long-term follow-up.
- Develop a plan for overcoming barriers to the appropriate use of DOACs for the acute treatment and secondary prevention of VTE.
Faculty
Alpesh Amin, M.D., MBA, FACC, MACP, SFHM
Thomas & Mary Cesario Chair of Medicine
Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering
Executive Director, Hospitalist Program
Medical Director, Anticoagulation Services
University of California, Irvine
Irvine, California
Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, is the Thomas & Mary Cesario Chair of the Department of Medicine at the University of California, Irvine (UCI). He is Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering at UCI. He is also founder and executive director of the Hospitalist Program. At UCI, Dr. Amin has served as Vice Chair for Clinical Affairs and Quality, Chief of the Division of General Internal Medicine (GIM), Associate Program Director of the Internal Medicine Residency Program, and Medicine Clerkship Director. Dr. Amin obtained his Doctor of Medicine degree at Northwestern University Medical School in Chicago, and he completed his internship and residencies in internal medicine, including a chief residency, at UCI. He also earned a healthcare MBA degree at UCI. Dr. Amin is the first hospitalist to be named chief of a division of GIM, and then subsequently the first hospitalist to be named chair of a department of medicine nationally.
Throughout his career, Dr. Amin has been innovative in clinical, quality, and educational program development. He has advised the Hamad Medical Corporation (HMC) in Doha, Qatar on quality improvement efforts across eight hospitals under the national health ministry council. He has developed processes to improve patient care delivery looking at ways to reduce readmission and avoidable admissions, decrease length of stay and mortality, and improve customer service. Dr. Amin is an expert in implementation science and measuring outcomes to improve sustainable results. He has also applied information technology to improve the delivery of care through development of projects such as NHCPlus, eConsults, and Apps for Safe Anticoagulation Use.
During the course of his career, Dr. Amin has served as principal investigator, co-investigator, and faculty sponsor on clinical trials and research projects focusing on clinical topics, such as venous thromboembolism, pneumonia, and heart failure. His research interest is in health outcomes related to patient safety, quality improvement, and medical education. He is a member of Society of Hospital Medicine (SHM), American College of Physicians (ACP), Society of General Internal Medicine, Academic Chiefs and Leaders of General Internal Medicine (ACLGIM), Academic Alliance of Internal Medicine, and Association of Professors of Medicine. Within SHM, he has served as the Annual Meeting Course Director and on the Board of Directors. Dr. Amin has authored or co-authored over 170 peer-reviewed articles. He is the co-editor and co-author of Core Competencies for Hospital Medicine by SHM. Dr. Amin is also co-editor of the book, Contemporary Hospitalist Guide to Anticoagulation.
Dr. Amin has been honored by being named a Master of ACP, Senior Fellow of SHM, and Fellow of American College of Cardiology. He also has been awarded the ACP Special Recognition Award, ACP Top 10 Hospitalist Award, Orange County Physician of Excellence Award, and he was named one of “America’s Top Physicians” by the Consumers’ Research Council of America. In addition, he received the Alfred Soffer Award from ACCP, Venous Research Award for Quality Improvement and Implementation of Best Practices from the Venous Disease Coalition (VDC)/Vascular Disease Foundation (VDF), Exceptional Leadership Award from ACLGIM, CDC Healthcare-associated VTE Prevention Champion, and HMC Star of Excellence Award. He founded and directs the UCI Anticoagulation Clinic, which is recognized nationally as an AC Forum Center of Excellence.
John Fanikos, R.Ph., MBA
Executive Director of Pharmacy Services
Brigham and Women’s Hospital
Adjunct Professor of Clinical Pharmacy
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts
John Fanikos, R.Ph., MBA, is Executive Director of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. He is responsible for the overall Pharmacy Department operations and its financial performance. Mr. Fanikos also serves as Adjunct Professor of Clinical Pharmacy at Massachusetts College of Pharmacy and Health Sciences. He earned his Bachelor of Science degree in Pharmacy at Massachusetts College of Pharmacy and his Master of Business Administration degree at Northeastern University. He completed an ASHP-accredited residency at BWH.
Mr. Fanikos has served in a number of different roles at BWH, including investigational drug pharmacist, inpatient and outpatient pharmacy supervisor, clinical preceptor, and pharmacy administrator. While fulfilling these roles, he has worked with patients on orthopedic, oncology, cardiology, and general medicine units. For the past 25 years, he has worked closely with the BWH Thromboembolism Research Group, and he has authored and co-authored many articles and textbook chapters on anticoagulant and antiplatelet medications. His research focus has been identifying and avoiding the problems and pitfalls of their use.
Mr. Fanikos is a member of the National Comprehensive Cancer Network (NCCN) panel that crafts guidelines for the treatment and prevention of thromboembolic disease. He serves as the treasurer and sits on the Board of Directors for the North American Thrombosis Forum (NATF), a nonprofit organization that provides a platform for those interested in thrombotic disorders to enhance disease education, awareness, advocacy, research, and prevention. He also serves on the Board of Directors for the Hospital Quality Foundation (HQF). Like NATF, HQF is a 503C charitable organization, and it is dedicated to improving the quality of healthcare by supporting the development and delivery of education related to medical practice. Mr. Fanikos is Past President of the Massachusetts Society of Health-System Pharmacists.
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
- Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, and Portola Pharmaceuticals, Inc. (Faculty and Steering Committee)
- John Fanikos, R.Ph., MBA, declares that he has served on an advisory board for Portola Pharmaceuticals, Inc. and as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc. (Faculty)
- Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, declares that he has served as a consultant for Bristol-Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. (Steering Committee)
- All other faculty and planners report no financial relationships relevant to this activity.
Methods and CE Requirements
This is an online activity consisting of audio and slides, an assessment, and a course evaluation. Participants should claim CE credit for this home-study educational activity only if they have not claimed credit for the live activity. Participants must view the entire presentation, take the activity assessment (a minimum score of 70% is required), and complete the course evaluation to receive CE credit. The handout includes slides and the assessment for your reference.
To access the activity, click "Launch Presentation" below. On the last slide of the presentation you must click the “Close Activity and Process CE” button to link to ASHP’s elearning portal to complete the process for obtaining credit. Per ACPE, CPE credit must be claimed no later than 60 days from the date of the live activity or completion of a home-study activity. CPE credit will be reported directly to CPE Monitor.
Agenda
Clinical Case Studies in Venous Thromboembolism: Using Direct Oral Anticoagulants for Treatment and Secondary Prevention
Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, and John Fanikos, R.Ph., MBA
Launch Presentation (60 minutes)*
*Allow additional time to complete the assessment and evaluation.
